Impact of allopurinol on risk of myocardial infarction. Issue 5 (6th January 2014)

• Record Type: Journal Article
• Authors: Grimaldi-Bensouda, L; Alpérovitch, A; Aubrun, E; Danchin, N; Rossignol, M; Abenhaim, L; Richette, P
• Other Names: Fromage Philippe collab.; Furber Alain collab.; Mery Denis collab.; Jabali Adnan El collab.; Banos Jean-Luc collab.; Tarabbia Philippe collab.; Sedighian Shahin collab.; Lallemant Robert collab.; Kadri Attia collab.; Ovize Michel collab.; Saint-Mézard Georges collab.; Brandstatt Philippe collab.; Koujan Bassel collab.; Amonchot Aimé collab.; Gouvion Thomas collab.; Ouanes Kamel collab.; Cottin Yves collab.; Zaouali Hocine collab.; Dormagen Véronique collab.; Afif Zahi collab.; Godenir Jean Philippe collab.; Alary Jean Philippe collab.; Pierrard Bruno collab.; Imianitoff Manuel collab.; Bessede Gérard collab.; Vaquette Bruno collab.; Martelet Michel collab.; Mouallem Joseph collab.; Sader Raif collab.; Gorka Hervé collab.; Rosak Philippe collab.; Viallet Michel collab.; Mokaddem Jazila collab.; Brefort Gérard collab.; Dahmani Noureddine collab.; Nallet Olivier collab.; Guillot Philippe collab.; Leclercq Florence collab.; Jamon Yann collab.; Tcheng Emmanuel collab.; Dibon Olivier collab.; Chaib Aurès collab.; Lozinguez Olivier collab.; Steg Gabriel collab.; Delarche Nicolas collab.; Boureux Christian collab.; Merle Erick collab.; Boukhsibi Fatima collab.; Rivet Charlotte Mestrallet collab.; Broin Patrick collab.; Boulain Luc collab.; Ferron Bertrand collab.; Hajmoussa Elian collab.; Pradies Felix collab.; Destrac Sylvain collab.; Prouteau Nathalie collab.; Heiligenstein Daniel collab.; Galinier Michel collab.; Banayan Jonathan collab.; Goburdhun Chandrah collab.; Dobocan Craciun Augusta collab.; Zylberberg Michel collab.; Guéranger Pierre collab.;
• Is Part Of: Annals of the rheumatic diseases. Volume 74:Issue 5(2015)
• Page Start: 836
• Page End: 842
• Publication Date: 2014-01-06
• Subjects: Gout -- Cardiovascular Disease -- Treatment; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-202972
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Gout therapy includes xanthine oxidase inhibitors (XOI) and colchicine, which have both been associated with decreased cardiovascular risk. However, their effects on major cardiac events, such as myocardial infarction (MI), need to be investigated further. Objectives: To investigate whether XOIs and colchicine are associated with decreased risk of MI. Methods: This case-control study compared patients with first-ever MI and matched controls. Cases were recruited from the Pharmacoepidemiological General Research on MI registry. Controls were selected from a referent population (n=8444) from general practice settings. Results: The study sample consisted of 2277 MI patients and 4849 matched controls. Use of allopurinol was reported by 3.1% of cases and 3.8 of controls, and 1.1% of cases and controls used colchicine. The adjusted OR (95% CI) for MI with allopurinol use was 0.80 (0.59 to 1.09). When using less stringent matching criteria that allowed for inclusion of 2593 cases and 5185 controls, the adjusted OR was 0.73 (0.54 to 0.99). Similar results were found on analysis by sex and hypertension status. Colchicine used was not associated with a decreased risk of MI (aOR=1.17 (0.70 to 1.93)). Conclusions: Allopurinol may be associated with a reduced risk of MI. No decreased risk of MI was found in colchicine users. Besides its urate-lowering property, allopurinol might have a cardioprotective effect.